Enemeez® Pharmacoeconomic Evaluation
Overview
A study conducted by the VA investigated the mean duration and quality of bowel care when comparing bisacodyl suppository and the docusate sodium mini-enema. In a randomized and non-randomized controlled trial, findings revealed a notable decrease in bowel care time when using a docusate sodium mini-enema compared to a bisacodyl suppository.
Treatment Outcome Cost Comparison Summary
Clinical Outcomes Impacting Facility Costs
Bisacodyl users are twice as likely to have an episode of incontinence following a bowel care session when compared to docusate sodium mini-enema users.
A pharmacoeconomic evaluation showed that when using Enemeez®, some patients reduced their bowel care time by 1 hour or more daily, thus reducing the time needed for a personal care attendant.
- In addition, the reduced time spent on a commode may reduce the risk of pelvic ulcer development. Incontinent patients are 22 times more likely to develop a pressure ulcer. The cost to treat can be upwards of $70,000.
- Prolonged bowel care time or fatigue after bowel care often interferes with a patient’s participation in therapy
Cost Comparison Summary
 |
 |
|---|
Bowel Care Time Summary
|
 |
|---|
Clinical Pharmacoeconomics
What does an ineffective bowel care protocol cost your facility?
- The total annual labor and supply cost in 2002 per long term care resident with constipation was $2,253.8*
- 46% of long-term care residents experience fecal incontinence on a regular basis.
- The mean time spent each day dealing with incontinence was 52.5 minutes per patient or $27.19 per day, per patient.
The total annual cost of incontinence per patient was $16,976.
